Recent Updates
Recently added Catalysts
ARCT Positive Sentiment

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

Wednesday, September 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arcturus Therapeutics announced positive interim results from its Phase 2 trial of ARCT-810 for ornithine transcarbamylase deficiency. The company also unveiled its next-generation mRNA delivery platform, LUNAR 2.0™, which aims to improve therapeutic delivery. This development highlights Arcturus's commitment to advancing treatments for liver and respiratory diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Interim Phase 2 results for ARCT-810 show encouraging outcomes.
  • Introduction of LUNAR 2.0™ enhances mRNA delivery capabilities.
  • Focus on liver and respiratory therapeutics indicates strong pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
5%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
ARCT-2303
Phase 3 · COVID-19

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company’s next-generation mRNA delivery platform, and additional liver pipeline programs. “The ARCT-810 Phase 2 interim results validate Arcturus’ m

Frequently Asked Questions

What are the interim results for ARCT-810?

The interim Phase 2 results for ARCT-810 show encouraging outcomes in treating OTC deficiency.

What is the LUNAR 2.0™ platform?

LUNAR 2.0™ is Arcturus's next-generation mRNA delivery platform aimed at enhancing therapeutic delivery.

What diseases does Arcturus focus on?

Arcturus Therapeutics focuses on developing therapeutics for liver and respiratory diseases.

What is OTC deficiency?

OTC deficiency is a genetic disorder that affects the body's ability to remove ammonia from the bloodstream.

ShareAdd on Google
Tags: ARCT Viatris Investor Conferences Healthcare Arcturus Therapeutics ARCT-810 LUNAR 2.0 mRNA delivery OTC deficiency
Last updated: Sep 23, 2026

Biotech snapshot

Cash runway
$191M liquidity · $7M/mo burn
~28 mo
Minimal dilution risk
Lead asset
ARCT-2303Phase 3
COVID-19 →

Catalyst track record

+36%
best trade around ARCT's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ARCT.

See every catalyst's timing & PoA →